ReviewBioMed research international2013
Nanocarriers for diagnosis and targeting of breast cancer.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 103 citations in OpenAlex.
- NbRSC advances · 2026Article
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026Review
- Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- A double-edged sword effect of silver nanoparticles on angiogenesis in 4T1 breast cancer-bearing mice.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A quality-by-design approach to develop abemaciclib solid lipid nanoparticles for targeting breast cancer cell lines.Therapeutic delivery · 2025Article
- Leveraging nanostructured lipid carriers to enhance targeted delivery and efficacy in breast cancer therapy: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Preparation andACS omega · 2023Article
- ROS Generative Black Phosphorus-Tamoxifen Nanosheets for Targeted Endocrine-Sonodynamic Synergistic Breast Cancer Therapy.International journal of nanomedicine · 2023Article
- Preparation and Evaluation of Diosmin-Loaded Diphenylcarbonate-Cross-Linked Cyclodextrin Nanosponges for Breast Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Genome-wide expression reveals potential biomarkers in breast cancer bone metastasis.Journal of integrative bioinformatics · 2022Article
- Carboxyl-Functionalized Carbon Nanotubes Loaded with Cisplatin Promote the Inhibition of PI3K/Akt Pathway and Suppress the Migration of Breast Cancer Cells.Pharmaceutics · 2022Article
- Exogenous Contrast Agents in Photoacoustic Imaging: An In Vivo Review for Tumor Imaging.Nanomaterials (Basel, Switzerland) · 2022Review
- Development and evaluation of luteolin loaded pegylated bilosome: optimization,Drug delivery · 2021Article
- Bioactive nanotherapeutic trends to combat triple negative breast cancer.Bioactive materials · 2021Review
- A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.Scientific reports · 2021Article
- Concept Design, Development and Preliminary Physical and Chemical Characterization of Tamoxifen-Guided-Mesoporous Silica Nanoparticles.Molecules (Basel, Switzerland) · 2021Article
- Design and Characterization of Liposomal Methotrexate and Its Effect on BT-474 Breast Cancer Cell Line.Medical journal of the Islamic Republic of Iran · 2021Article
- Drug Delivery Systems of Natural Products in Oncology.Molecules (Basel, Switzerland) · 2020Review
- Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles.Molecules (Basel, Switzerland) · 2020Review
- Recent advances in nanotheranostics for triple negative breast cancer treatment.Journal of experimental & clinical cancer research : CR · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer nanotherapeutics is consistently progressing and being used to remove the various limitations of conventional method available for the diagnosis and treatment of breast cancer. Nanoparticles provide an interdisciplinary area for research in imaging, diagnosis, and targeting of breast cancer. With advanced physicochemical properties and better bioavailability, they show prolonged blood circulation with efficient tumor targeting. Passive targeting mechanisms by using leaky vasculature, tumor microenvironment, or direct local application and active targeting approaches using receptor antibody, amplification in the ability of nanoparticles to target specific tumor can be achieved. Nanoparticles are able to reduce cytotoxic effect of the active anticancer drugs by increasing cancer cell targeting in comparison to conventional formulations. Various nanoparticles-based formulations are in the preclinical and clinical stages of development; among them, polymeric drug micelles, liposomes, dendrimer, carbon nanotubes, and nanorods are the most common. In this review, we have discussed the role of nanoparticles with respect to oncology, by particularly focusing on the breast cancer and various nanodelivery systems used for targeting action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.